Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issue
23-4
Table of Contents
Editors Selection
Glaucoma Dialogue
Glaucoma Opinion
Abstracts
Abstracts
Abstracted Journals
Classification List
Index of Authors
Search
Home
Issue 23-4
News Flashes
advertisement
News Flashes
IGR 23-4
This study is compelling, showing a potential contribution of Müller cells changes that precede statistically significant elevations in IOP
These results highlight the prevalence of treatment failures in routine clinical practice
The main limitation of this study is that it is cross-sectional and provides evidence for an association but not a causal relationship
The study findings significantly lack generalizability as the population was ethnically homogenous and the data lacked information about glaucomatous status or past exposure to IOP lowering pharmacotherapy
Another issue is that the study excluded those that developed OSA, and would be more likely to create attrition from the control group and increase the likelihood of an association in the Study group. This might magnify the treatment of OSA
While the benefits to glaucoma of treating OSA is still controversial, it is important to refer patients with suspected sleep apnea for testing because treatment of sleep apnea has large health benefits for other health conditions
It remains to be seen if this strategy can mediate consistent neuroprotection or neuroenhancement in human glaucoma
The proportion of eye drops successfully reaching the eye was actually lower using the nose-pivoted delivery device, though this was not statistically significant (64% versus 59%)
Once the TM cells or Schlemn's canal endothelial cells are damaged and lose their function, the induction of MMP3 may not be effective
The 14-year number needed to treat to prevent one case of PAC was 12.4 compared to 44 at 6 years
The main limitation of the study is the generalizability of the results
As the annual incidence of PAC was low and AAC and PACG were relatively rare in the community-based population with PACS over the long term, clinicians should assess the risk factors for progression when treating patients with PACS and prophylactic LPI should be recommended preferentially to those at the highest risk of angle closure
This study's results, if replicated in other populations and other glaucoma types would place the XEN gel stent as a viable less-invasive alternative to trabeculectomy, especially when efficacy, safety, and patients' quality of life are weighted against each other
One additional topic that is pertinent to the entire MIGS space is the health economics of MIGS and cost implications of surgical choices
IOP fluctuation was significantly greater postoperative (4 vs. 11 eyes showing IOP fluctuation >6mmHg), and the authors hypothesized that procedures aiming to reduce aqueous production may not blunt IOP fluctuation
Although reducing the burden of multiple medications is desirable, there is a need to assess more clinically meaningful endpoints of the relatively new glaucoma surgical procedures to enable a better decision making process, particularly to properly allocate the limited resources for preventing glaucoma blindness worldwide
The relatively modest sample size of the European validation set elicits concerns, while the inherent dissimilarity in demographic metrics between the European and Asian datasets further compounds the issue
Despite the limitations, this study adds to the growing body of evidence supporting a protective effect of dietary niacin on glaucoma risk
Issue
23-4
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
24-1 (2024)
23-4 (2023)
23-3 (2023)
23-2 (2023)
23-1 (2022)
22-4 (2022)
22-3 (2022)
22-2 (2021)
22-1 (2021)
21-4 (2021)
21-3 (2021)
21-2 (2021)
21-1 (2020)
20-4 (2020)
20-3 (2020)
20-2 (2019)
20-1 (2019)
19-4 (2019)
19-3 (2018)
19-2 (2018)
19-1 (2018)
18-4 (2017)
18-3 (2017)
18-2 (2017)
18-1 (2017)
17-4 (2016)
17-3 (2016)
17-2 (2016)
17-1 (2016)
16-4 (2015)
16-3 (2015)
16-2 (2015)
16-1 (2014)
15-4 (2014)
15-3 (2014)
15-2 (2013)
15-1 (2013)
14-4 (2013)
14-3 (2013)
14-2 (2013)
14-1 (2012)
13-4 (2012)
13-3 (2011)
13-2 (2011)
13-1 (2011)
12-4 (2011)
12-3 (2010)
12-2 (2010)
12-1 (2010)
11-4 (2010)
11-3 (2009)
11-2 (2009)
11-1 (2009)
10-4 (2009)
10-3 (2008)
10-2 (2008)
10-1 (2008)
9-4 (2008)
9-3 (2007)
9-2 (2007)
9-1 (2007)
8-4 (2007)
8-3 (2006)
8-2 (2006)
8-1 (2006)
7-3 (2006)
7-2 (2005)
7-1 (2005)
6-3 (2005)
6-2 (2004)
6-1 (2004)
5-3 (2004)
5-2 (2003)
5-1 (2003)
4-3 (2003)
4-2 (2002)
4-1 (2002)
3-3 (2002)
3-2 (2001)
3-1 (2001)
2-3 (2001)
2-2 (2000)
2-1 (2000)
1-3 (2000)
1-2 (1999)
1-1 (1999)
advertisement